Literature DB >> 8963656

Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation.

R A Wallis1, K L Panizzon, J M Girard.   

Abstract

N-Methyl-D-aspartate (NMDA) receptor activation is known to contribute to neuronal damage from head trauma. Additionally, NMDA neurotoxicity occurs in part through the generation of nitric oxide (NO), and injury from NO has been shown to be mediated by ADP-ribosylation. Therefore, we investigated whether inhibitors of NO and ADP-ribosylation would protect against acute CA1 traumatic neuronal injury in hippocampal slices subjected to fluid percussion. Treatment with the nitric oxide synthase (NOS) inhibitor, methyl-L-arginine 170 microM for 35 min after trauma injury, improved CA1 antidromic population spike (PS) recovery to 91 +/- 2%, compared to unmediated slices which recovered to only a mean of 20 +/- 4%, 90 min after trauma. Similarly, hemoglobin 50 microM, which directly binds NO, protected against traumatic neuronal injury and yielded a mean CA1 PS recovery of 92 +/- 1%. Treatment with inhibitors of poly-ADP-ribosylation was also strongly protective, with the vitamin nicotinamide 10 mM and 3-aminobenzamide 1 mM yielding PS recoveries of 98 +/- 2% and 90 +/- 3%, respectively. Protection was also seen with inhibitors of mono-ADP-ribosylation, including novobiocin 500 microM and meta-iodobenzylguanidine 20 microM which yielded recoveries of 89 +/- 6% and 96 +/- 26%. Novobiocin also protected against direct application of NO and NMDA. These findings suggest that NO and ADP-ribosylation are mediators of acute traumatic neuronal injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8963656     DOI: 10.1016/0006-8993(95)01278-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

Review 1.  Biomechanics of concussion.

Authors:  David F Meaney; Douglas H Smith
Journal:  Clin Sports Med       Date:  2011-01       Impact factor: 2.182

Review 2.  Antioxidant therapies for traumatic brain injury.

Authors:  Edward D Hall; Radhika A Vaishnav; Ayman G Mustafa
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

3.  Potassium-stimulated taurine release and nitric oxide synthase activity during quinolinic acid lesion of the rat striatum.

Authors:  R Böckelmann; M Reiser; G Wolf
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

4.  The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated "anti-apoptotic" pathways.

Authors:  Zhao-Zhong Chong; Shi-Hua Lin; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-10       Impact factor: 1.990

Review 5.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

6.  Nicotinamide attenuates focal ischemic brain injury in rats: with special reference to changes in nicotinamide and NAD+ levels in ischemic core and penumbra.

Authors:  Fumiko Sadanaga-Akiyoshi; Hiroshi Yao; Sei-ichi Tanuma; Tatsuo Nakahara; Jong Soon Hong; Setsuro Ibayashi; Hideyuki Uchimura; Masatoshi Fujishima
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 7.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 8.  In-vitro approaches for studying blast-induced traumatic brain injury.

Authors:  Yung Chia Chen; Douglas H Smith; David F Meaney
Journal:  J Neurotrauma       Date:  2009-06       Impact factor: 5.269

Review 9.  Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.

Authors:  Valerie C Besson
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 10.  The vitamin nicotinamide: translating nutrition into clinical care.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Molecules       Date:  2009-09-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.